Loading...
PhD Boštjan Markelc

PhD Boštjan Markelc
no.: 32175 source: ARIS

researcher – active in research organisation
Foreign language skills
Research activity

Code Science Field Subfield
3.00.00  Medical sciences     
3.04.00  Medical sciences  Oncology   

Code Science Field
B200  Biomedical sciences  Cytology, oncology, cancerology 
Points
715.4
A''
198.37
A'
500.71
A1/2
584.58
CI10
1,354
CImax
142
h10
19
A1
2.76
A3
4.65
Data for the last 5 years (citations for the last 10 years) on October 7, 2024; A3 for period 2018-2022 (update for tender in 2023: YES)
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Database Linked records Citations Pure citations Average pure citations
WoS 66  1,564  1,231  18.65 
Scopus 65  1,708  1,361  20.94 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 Iva Šantek  Bologna doctoral studies    55825 
2 PhD Tim Božič  Bologna doctoral studies  10/1/2018 - 9/30/2022  51848 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group
Full time employment (100%, RD:100%)  Institute of Oncology Ljubljana  Department of research 
Research projects Legend
source: ARIS
no. Code Title Period Head No. of publications
1. J3-50108  DEBIO 1143 has a potential to increase effectiveness of electrochemotherapy and radiotherapy in HPV positive and HPV negative Head and Neck Cancers   2023 - 2024  PhD Katarina Žnidar  2,254 
2. J4-50150  Erythrocyte membrane-based nanocarriers for gene silencing cancer therapy   2023 - 2024  PhD Nina Kostevšek  4,014 
3. L3-50111  Gene immuno-therapy of solid tumors based on mRNA encoding interleukin-12: So-rIL   2023 - 2024  PhD Maja Čemažar  2,900 
4. J3-50110  Intratumoral mRNA electrotransfer: establishment and preclinical proof of concept   2023 - 2024  PhD Katja Uršič Valentinuzzi  3,189 
5. J2-50068  Safety and efficacy of high frequency electrochemotherapy - clinical device development   2023 - 2024  PhD Matej Reberšek  3,542 
6. BI-US/24-26-093  The role of extracellular matrix in the development of normal and tumor vasculature   2024  PhD Boštjan Markelc  240 
7. L7-4491  Development of integrated multi-channel artificial nose for detection of cancer   2022 - 2024  PhD Igor Muševič  5,607 
8. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   2022 - 2024  PhD Lucija Peterlin Mašič  6,294 
9. J3-4504  Uncovering the glioblastoma microenvironment to enhance the therapy   2022 - 2024  PhD Metka Novak  1,840 
10. J3-3083  Vascularization and vascular effects as predictive factors for local ablative techniques   2021 - 2024  PhD Gregor Serša  6,911 
11. BI-US/22-24-070  Demonstration of the possibility of linking results between three-dimensional biometric vessel models and tumor vessels in vivo   2022 - 2024  PhD Boštjan Markelc  240 
12. J3-2528  Immuno gene electrotransfer of IL-12 and IL-2 in immunologically cold/hot tumors   2020 - 2023  PhD Maja Čemažar  3,244 
13. J3-2529  Role of endothelium in tumor response to radiotherapy   2020 - 2023  PhD Boštjan Markelc  3,523 
14. J3-9269  Clinico-pharmacological approach to optimize the therapeutic bleomycin concentration in patients undergoing electrochemotherapy   2018 - 2021  PhD Gregor Serša  3,605 
15. J2-9225  Non-invasive technique for Cell Membrane Permeabilization using pulsed electromagnetic fields   2018 - 2021  PhD Damijan Miklavčič  2,945 
16. J3-8202  Time-lapse intra-vital imaging of immune response after electrochemotherapy induced in situ vaccination and Interleukin-12 gene therapy boost   2018 - 2020  PhD Maja Čemažar  3,624 
17. J4-5529  Nitroxoline and its derivatives as new antitumour drugs   2013 - 2014  PhD Janko Kos  6,099 
18. L2-4105  Development and validation of a software for numerical modeling of in vivo electroporation - in silico electroporation   2011 - 2012  PhD Damijan Miklavčič  4,914 
19. J3-4259  Preparation and validation of therapeutic plasmids without selection gene for antibiotic resistance for cancer gene therapy using inducible and tissue-specific promoters   2011 - 2012  PhD Maja Čemažar  6,002 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head No. of publications
1. P3-0003  Development and evaluation of new approaches to cancer treatment   2022 - 2024  PhD Gregor Serša  4,067 
2. I0-0059  Infrastrukturna dejavnost ONKOLOŠKI INŠTITUT (Slovene)   2022 - 2024  PhD Boštjan Markelc  581 
3. P3-0003  Development and evaluation of new approaches to cancer treatment   2018 - 2021  PhD Gregor Serša  3,352 
4. P3-0003  Development and evaluation of new approaches to cancer treatment   2009 - 2012  PhD Gregor Serša  4,105 
We were not given permission by the researcher to publish data.
Views history
Favourite